TY  - JOUR
AU  - Al-Monajjed, Rouvier
AU  - Boschheidgen, Matthias
AU  - Lakes, Jale
AU  - Krilaviciute, Agne
AU  - Radtke, Jan-Philipp
AU  - Schlemmer, Heinz-Peter
AU  - Bonekamp, David
AU  - Herkommer, Kathleen
AU  - Jahnen, Matthias
AU  - Gschwend, Jürgen E
AU  - Düx, Daniel
AU  - Wacker, Frank
AU  - Makowski, Marcus R
AU  - Sauter, Andreas
AU  - Kuczyk, Markus A
AU  - Harke, Nina
AU  - Debus, Jürgen
AU  - Grott, Christoph
AU  - Arsov, Christian
AU  - Seibold, Petra
AU  - Benner, Axel
AU  - Hadaschik, Boris
AU  - Giesel, Frederik
AU  - Kristiansen, Glen
AU  - Antoch, Gerald
AU  - Becker, Nikolaus
AU  - Kaaks, Rudolf
AU  - Albers, Peter
AU  - Schimmöller, Lars
TI  - Value of Additional Systematic Cores During Magnetic Resonance Imaging-guided Targeted Biopsy in Prostate Cancer Screening for Young Men: Results from the PROBASE Trial.
JO  - European urology oncology
VL  - nn
SN  - 2588-9311
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2025-02369
SP  - nn
PY  - 2025
N1  - #EA:C130#LA:C130# / epub
AB  - While magnetic resonance imaging (MRI)-guided targeted biopsy (TBx) is becoming an integral part of early detection of prostate cancer (PC), its role in screening of younger men remains unclear. We analyzed the additional value of systematic biopsy (SBx) in improving detection of clinically significant PC (csPC).A total of 525 men aged 45-54 yr with confirmed prostate-specific antigen ≥3.0 ng/ml underwent multiparametric MRI followed by combined TBx and SBx between February 2014 and August 2023 within a multicenter prospective screening trial in Germany. Software-based MRI/ultrasound fusion TBx (2 cores per lesion) combined with SBx was performed via a transrectal or transperineal approach. The primary objective was to analyze differences in csPC detection rates between SBx and TBx in relation to MRI. Secondary objectives were detection rates by International Society of Urological Pathology grade group (GG) and the distribution of SBx and/or TBx findings.PC was detected in 209 men (39
KW  - Fusion biopsy (Other)
KW  - Magnetic resonance imaging (Other)
KW  - Prostate cancer (Other)
KW  - Prostate-specific antigen (Other)
KW  - Risk-adapted screening (Other)
KW  - Ultrasound (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41219113
DO  - DOI:10.1016/j.euo.2025.10.014
UR  - https://inrepo02.dkfz.de/record/305749
ER  -